First-line stimulant therapies for attention deficit hyperactivity disorder (ADHD) implicate the forebrain monoaminergic neurotransmitter systems of dopamine, noradrenaline and serotonin. However, there is no curative treatment. Investigation of neurochemical monoaminergic changes, followed by curative treatments, requires sub-type specific animal models. In a novel rat model of the hyperactive-impulsive and attentive subtype of ADHD, specific changes in forebrain monoamines, and correlations…
